Differences Between Patients Undergoing Initial Biopsy or Resection (n = 542, 6 Cases Missing)
| . | Biopsy (N = 154) . | Resection (N = 388) . | P-Value . |
|---|---|---|---|
| Age, Mean (SD) | 53.0 (14.9) | 44.0 (14.2) | <.001 |
| Female, n (%) | 76 (49.4) | 168 (43.3) | .20 |
| Year of Treatment, Median (IQR) | 2010 (2008-2013) | 2011 (2009-2013) | .09 |
| Tumor Size, n (%) | N = 130 | N = 349 | .10 |
| < 4 cm | 59 (45.4) | 134 (38.4) | |
| 4-6 cm | 41 (31.5) | 148 (42.4) | |
| > 6 cm | 30 (23.1) | 67 (19.2) | |
| Main Lobe Involved, n (%) | <.001 | ||
| Frontal | 63 (40.9) | 219 (56.4) | |
| Temporal | 29 (18.8) | 94 (24.2) | |
| Parietal | 24 (15.6) | 47 (12.1) | |
| Occipital | 8 (5.2) | 12 (3.1) | |
| Overlapping Sites | 8 (5.2) | 6 (1.6) | |
| Not Specified | 22 (14.3) | 10 (2.6) | |
| Laterality, n (%) | N = 149 | N = 385 | <.001 |
| Left | 77 (51.7) | 195 (50.6) | |
| Right | 58 (38.9) | 182 (47.3) | |
| Bilateral | 14 (9.4) | 8 (2.1) | |
| Multifocal, n (%) | 34 (22.1) | 23 (5.9) N = 387 | <.001 |
| Bilateral OR Multifocal, n (%) | 38 (24.7) | 25 (6.5) N = 387 | <.001 |
| Asymptomatic, n (%) | 7 (5.0) N = 141 | 29 (7.8) N = 374 | .27 |
| Focal Deficit, n (%) | 76 (50.0) N = 152 | 123 (32.7) N = 376 | <.001 |
| Seizures, n (%) | 86 (61.0) N = 141 | 246 (67.6) N = 364 | .16 |
| ICP-Related Symptoms, n (%) | 34 (24.3) N = 140 | 90 (24.8) N = 363 | .91 |
| Performance Status, n (%) | N = 149 | N = 380 | .001 |
| 0 | 67 (45.0) | 229 (60.3) | |
| 1 | 44 (29.5) | 93 (24.5) | |
| 2 | 24 (16.1) | 48 (12.6) | |
| 3 | 11 (7.4) | 6 (1.6) | |
| 4 | 3 (2.0) | 4 (1.1) | |
| Weeks from Imaging to Surgery, Median (IQR) | 4 (2-8.75) N = 152 | 5 (3-12) N = 384 | .10 |
| Histopathology, n (%) | <.001 | ||
| Astrocytoma | 120 (77.9) | 152 (39.2) | |
| Oligoastrocytoma | 11 (7.1) | 171 (44.1) | |
| Oligodendroglioma | 23 (14.9) | 65 (16.8) | |
| Postop Complication, n (%) | 14 (9.1) | 117 (30.2) | <.001 |
| Postop New Neurological Deficit, n (%) | 8 (6.2) N = 130 | 78 (22.5) N = 347 | <.001 |
| Postop New Seizure, n (%) | 1 (0.8) N = 130 | 10 (2.9) N = 346 | .17 |
| Postop Infection, n (%) | 3 (2.1) N = 141 | 11 (3.0) N = 361 | .57 |
| Postop VTE, n (%) | 3 (2.1) N = 141 | 7 (1.9) N = 361 | .89 |
| Postop Hematoma, n (%) | 3 (2.1) N = 141 | 23 (6.4) N = 361 | .05 |
| Reoperation due to Complication, n (%) | 5 (3.8) N = 130 | 23 (6.6) N = 346 | .25 |
| Neurosurgical Ward, Days (IQR) | 3 (2-5) | 5 (3-6) | <.001 |
| Planned Adjuvant Oncological Treatment, n (%) | 100 (87.0) | 231 (67.2) | <.001 |
| 30-day Mortality, n (%) | 2 (1.3) N = 153 | 5 (1.3) | .99 |
| 1-Year Mortality, n (%) | 41 (26.8) N = 153 | 21 (5.4) | <.001 |
| . | Biopsy (N = 154) . | Resection (N = 388) . | P-Value . |
|---|---|---|---|
| Age, Mean (SD) | 53.0 (14.9) | 44.0 (14.2) | <.001 |
| Female, n (%) | 76 (49.4) | 168 (43.3) | .20 |
| Year of Treatment, Median (IQR) | 2010 (2008-2013) | 2011 (2009-2013) | .09 |
| Tumor Size, n (%) | N = 130 | N = 349 | .10 |
| < 4 cm | 59 (45.4) | 134 (38.4) | |
| 4-6 cm | 41 (31.5) | 148 (42.4) | |
| > 6 cm | 30 (23.1) | 67 (19.2) | |
| Main Lobe Involved, n (%) | <.001 | ||
| Frontal | 63 (40.9) | 219 (56.4) | |
| Temporal | 29 (18.8) | 94 (24.2) | |
| Parietal | 24 (15.6) | 47 (12.1) | |
| Occipital | 8 (5.2) | 12 (3.1) | |
| Overlapping Sites | 8 (5.2) | 6 (1.6) | |
| Not Specified | 22 (14.3) | 10 (2.6) | |
| Laterality, n (%) | N = 149 | N = 385 | <.001 |
| Left | 77 (51.7) | 195 (50.6) | |
| Right | 58 (38.9) | 182 (47.3) | |
| Bilateral | 14 (9.4) | 8 (2.1) | |
| Multifocal, n (%) | 34 (22.1) | 23 (5.9) N = 387 | <.001 |
| Bilateral OR Multifocal, n (%) | 38 (24.7) | 25 (6.5) N = 387 | <.001 |
| Asymptomatic, n (%) | 7 (5.0) N = 141 | 29 (7.8) N = 374 | .27 |
| Focal Deficit, n (%) | 76 (50.0) N = 152 | 123 (32.7) N = 376 | <.001 |
| Seizures, n (%) | 86 (61.0) N = 141 | 246 (67.6) N = 364 | .16 |
| ICP-Related Symptoms, n (%) | 34 (24.3) N = 140 | 90 (24.8) N = 363 | .91 |
| Performance Status, n (%) | N = 149 | N = 380 | .001 |
| 0 | 67 (45.0) | 229 (60.3) | |
| 1 | 44 (29.5) | 93 (24.5) | |
| 2 | 24 (16.1) | 48 (12.6) | |
| 3 | 11 (7.4) | 6 (1.6) | |
| 4 | 3 (2.0) | 4 (1.1) | |
| Weeks from Imaging to Surgery, Median (IQR) | 4 (2-8.75) N = 152 | 5 (3-12) N = 384 | .10 |
| Histopathology, n (%) | <.001 | ||
| Astrocytoma | 120 (77.9) | 152 (39.2) | |
| Oligoastrocytoma | 11 (7.1) | 171 (44.1) | |
| Oligodendroglioma | 23 (14.9) | 65 (16.8) | |
| Postop Complication, n (%) | 14 (9.1) | 117 (30.2) | <.001 |
| Postop New Neurological Deficit, n (%) | 8 (6.2) N = 130 | 78 (22.5) N = 347 | <.001 |
| Postop New Seizure, n (%) | 1 (0.8) N = 130 | 10 (2.9) N = 346 | .17 |
| Postop Infection, n (%) | 3 (2.1) N = 141 | 11 (3.0) N = 361 | .57 |
| Postop VTE, n (%) | 3 (2.1) N = 141 | 7 (1.9) N = 361 | .89 |
| Postop Hematoma, n (%) | 3 (2.1) N = 141 | 23 (6.4) N = 361 | .05 |
| Reoperation due to Complication, n (%) | 5 (3.8) N = 130 | 23 (6.6) N = 346 | .25 |
| Neurosurgical Ward, Days (IQR) | 3 (2-5) | 5 (3-6) | <.001 |
| Planned Adjuvant Oncological Treatment, n (%) | 100 (87.0) | 231 (67.2) | <.001 |
| 30-day Mortality, n (%) | 2 (1.3) N = 153 | 5 (1.3) | .99 |
| 1-Year Mortality, n (%) | 41 (26.8) N = 153 | 21 (5.4) | <.001 |
Abbreviations: ICP, intracranial pressure; IQR, interquartile range; Postop, postoperative; VTE, venous thromboembolism.
When data are missing, the actual N is provided in individual cells.
Differences Between Patients Undergoing Initial Biopsy or Resection (n = 542, 6 Cases Missing)
| . | Biopsy (N = 154) . | Resection (N = 388) . | P-Value . |
|---|---|---|---|
| Age, Mean (SD) | 53.0 (14.9) | 44.0 (14.2) | <.001 |
| Female, n (%) | 76 (49.4) | 168 (43.3) | .20 |
| Year of Treatment, Median (IQR) | 2010 (2008-2013) | 2011 (2009-2013) | .09 |
| Tumor Size, n (%) | N = 130 | N = 349 | .10 |
| < 4 cm | 59 (45.4) | 134 (38.4) | |
| 4-6 cm | 41 (31.5) | 148 (42.4) | |
| > 6 cm | 30 (23.1) | 67 (19.2) | |
| Main Lobe Involved, n (%) | <.001 | ||
| Frontal | 63 (40.9) | 219 (56.4) | |
| Temporal | 29 (18.8) | 94 (24.2) | |
| Parietal | 24 (15.6) | 47 (12.1) | |
| Occipital | 8 (5.2) | 12 (3.1) | |
| Overlapping Sites | 8 (5.2) | 6 (1.6) | |
| Not Specified | 22 (14.3) | 10 (2.6) | |
| Laterality, n (%) | N = 149 | N = 385 | <.001 |
| Left | 77 (51.7) | 195 (50.6) | |
| Right | 58 (38.9) | 182 (47.3) | |
| Bilateral | 14 (9.4) | 8 (2.1) | |
| Multifocal, n (%) | 34 (22.1) | 23 (5.9) N = 387 | <.001 |
| Bilateral OR Multifocal, n (%) | 38 (24.7) | 25 (6.5) N = 387 | <.001 |
| Asymptomatic, n (%) | 7 (5.0) N = 141 | 29 (7.8) N = 374 | .27 |
| Focal Deficit, n (%) | 76 (50.0) N = 152 | 123 (32.7) N = 376 | <.001 |
| Seizures, n (%) | 86 (61.0) N = 141 | 246 (67.6) N = 364 | .16 |
| ICP-Related Symptoms, n (%) | 34 (24.3) N = 140 | 90 (24.8) N = 363 | .91 |
| Performance Status, n (%) | N = 149 | N = 380 | .001 |
| 0 | 67 (45.0) | 229 (60.3) | |
| 1 | 44 (29.5) | 93 (24.5) | |
| 2 | 24 (16.1) | 48 (12.6) | |
| 3 | 11 (7.4) | 6 (1.6) | |
| 4 | 3 (2.0) | 4 (1.1) | |
| Weeks from Imaging to Surgery, Median (IQR) | 4 (2-8.75) N = 152 | 5 (3-12) N = 384 | .10 |
| Histopathology, n (%) | <.001 | ||
| Astrocytoma | 120 (77.9) | 152 (39.2) | |
| Oligoastrocytoma | 11 (7.1) | 171 (44.1) | |
| Oligodendroglioma | 23 (14.9) | 65 (16.8) | |
| Postop Complication, n (%) | 14 (9.1) | 117 (30.2) | <.001 |
| Postop New Neurological Deficit, n (%) | 8 (6.2) N = 130 | 78 (22.5) N = 347 | <.001 |
| Postop New Seizure, n (%) | 1 (0.8) N = 130 | 10 (2.9) N = 346 | .17 |
| Postop Infection, n (%) | 3 (2.1) N = 141 | 11 (3.0) N = 361 | .57 |
| Postop VTE, n (%) | 3 (2.1) N = 141 | 7 (1.9) N = 361 | .89 |
| Postop Hematoma, n (%) | 3 (2.1) N = 141 | 23 (6.4) N = 361 | .05 |
| Reoperation due to Complication, n (%) | 5 (3.8) N = 130 | 23 (6.6) N = 346 | .25 |
| Neurosurgical Ward, Days (IQR) | 3 (2-5) | 5 (3-6) | <.001 |
| Planned Adjuvant Oncological Treatment, n (%) | 100 (87.0) | 231 (67.2) | <.001 |
| 30-day Mortality, n (%) | 2 (1.3) N = 153 | 5 (1.3) | .99 |
| 1-Year Mortality, n (%) | 41 (26.8) N = 153 | 21 (5.4) | <.001 |
| . | Biopsy (N = 154) . | Resection (N = 388) . | P-Value . |
|---|---|---|---|
| Age, Mean (SD) | 53.0 (14.9) | 44.0 (14.2) | <.001 |
| Female, n (%) | 76 (49.4) | 168 (43.3) | .20 |
| Year of Treatment, Median (IQR) | 2010 (2008-2013) | 2011 (2009-2013) | .09 |
| Tumor Size, n (%) | N = 130 | N = 349 | .10 |
| < 4 cm | 59 (45.4) | 134 (38.4) | |
| 4-6 cm | 41 (31.5) | 148 (42.4) | |
| > 6 cm | 30 (23.1) | 67 (19.2) | |
| Main Lobe Involved, n (%) | <.001 | ||
| Frontal | 63 (40.9) | 219 (56.4) | |
| Temporal | 29 (18.8) | 94 (24.2) | |
| Parietal | 24 (15.6) | 47 (12.1) | |
| Occipital | 8 (5.2) | 12 (3.1) | |
| Overlapping Sites | 8 (5.2) | 6 (1.6) | |
| Not Specified | 22 (14.3) | 10 (2.6) | |
| Laterality, n (%) | N = 149 | N = 385 | <.001 |
| Left | 77 (51.7) | 195 (50.6) | |
| Right | 58 (38.9) | 182 (47.3) | |
| Bilateral | 14 (9.4) | 8 (2.1) | |
| Multifocal, n (%) | 34 (22.1) | 23 (5.9) N = 387 | <.001 |
| Bilateral OR Multifocal, n (%) | 38 (24.7) | 25 (6.5) N = 387 | <.001 |
| Asymptomatic, n (%) | 7 (5.0) N = 141 | 29 (7.8) N = 374 | .27 |
| Focal Deficit, n (%) | 76 (50.0) N = 152 | 123 (32.7) N = 376 | <.001 |
| Seizures, n (%) | 86 (61.0) N = 141 | 246 (67.6) N = 364 | .16 |
| ICP-Related Symptoms, n (%) | 34 (24.3) N = 140 | 90 (24.8) N = 363 | .91 |
| Performance Status, n (%) | N = 149 | N = 380 | .001 |
| 0 | 67 (45.0) | 229 (60.3) | |
| 1 | 44 (29.5) | 93 (24.5) | |
| 2 | 24 (16.1) | 48 (12.6) | |
| 3 | 11 (7.4) | 6 (1.6) | |
| 4 | 3 (2.0) | 4 (1.1) | |
| Weeks from Imaging to Surgery, Median (IQR) | 4 (2-8.75) N = 152 | 5 (3-12) N = 384 | .10 |
| Histopathology, n (%) | <.001 | ||
| Astrocytoma | 120 (77.9) | 152 (39.2) | |
| Oligoastrocytoma | 11 (7.1) | 171 (44.1) | |
| Oligodendroglioma | 23 (14.9) | 65 (16.8) | |
| Postop Complication, n (%) | 14 (9.1) | 117 (30.2) | <.001 |
| Postop New Neurological Deficit, n (%) | 8 (6.2) N = 130 | 78 (22.5) N = 347 | <.001 |
| Postop New Seizure, n (%) | 1 (0.8) N = 130 | 10 (2.9) N = 346 | .17 |
| Postop Infection, n (%) | 3 (2.1) N = 141 | 11 (3.0) N = 361 | .57 |
| Postop VTE, n (%) | 3 (2.1) N = 141 | 7 (1.9) N = 361 | .89 |
| Postop Hematoma, n (%) | 3 (2.1) N = 141 | 23 (6.4) N = 361 | .05 |
| Reoperation due to Complication, n (%) | 5 (3.8) N = 130 | 23 (6.6) N = 346 | .25 |
| Neurosurgical Ward, Days (IQR) | 3 (2-5) | 5 (3-6) | <.001 |
| Planned Adjuvant Oncological Treatment, n (%) | 100 (87.0) | 231 (67.2) | <.001 |
| 30-day Mortality, n (%) | 2 (1.3) N = 153 | 5 (1.3) | .99 |
| 1-Year Mortality, n (%) | 41 (26.8) N = 153 | 21 (5.4) | <.001 |
Abbreviations: ICP, intracranial pressure; IQR, interquartile range; Postop, postoperative; VTE, venous thromboembolism.
When data are missing, the actual N is provided in individual cells.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
